Cargando…

Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants

The magnitude and duration of immune response to COVID-19 vaccination in older adults are known to be adversely affected due to immunosenescence and inflammaging. The threat of emerging variants warrants studies on immune response in older adults to primary vaccination and booster doses so as to und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patil, Dilip R., Shete, Anita M., Yadav, Pragya D., Sapkal, Gajanan N., Deshpande, Gururaj R., Kaushal, Himanshu, Mohandas, Sreelekshmy, Fulari, Siddharam, Jain, Rajlaxmi, Kumar, Ajay, Abraham, Priya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175569/ https://www.ncbi.nlm.nih.gov/pubmed/37187744 http://dx.doi.org/10.3389/fimmu.2023.1161571

Ejemplares similares

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
por: Yadav, Pragya D., et al.
Publicado: (2021)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model
por: Yadav, Pragya D., et al.
Publicado: (2022)

SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern
por: Mohandas, Sreelekshmy, et al.
Publicado: (2022)

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection
por: Mohandas, Sreelekshmy, et al.
Publicado: (2020)

A qualitative IgG ELISA for detection of SARS-CoV-2-specific antibodies in Syrian hamster serum samples
por: Shete, Anita, et al.
Publicado: (2021)

Study of Kyasanur forest disease viremia, antibody kinetics, and virus infection in target organs of Macaca radiata
por: Patil, Dilip R., et al.
Publicado: (2020)

SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient sera
por: Sahay, Rima R., et al.
Publicado: (2022)

Bbv-152: Subacute thyroiditis: case report
Publicado: (2022)

BBV-152: Myocarditis and myositis: case report
Publicado: (2022)

BBV-152: Herpes zoster: case report
Publicado: (2022)

BBV-152: Reactivation of uveitis : case report
Publicado: (2022)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG
por: Sapkal, Gajanan, et al.
Publicado: (2020)

BBV-152: Cutaneous small vessel vasculitis: case report
Publicado: (2021)

Bbv-152: Cutaneous small-vessel vasculitis: case report
Publicado: (2021)

Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022)

Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model
por: Yadav, Pragya, et al.
Publicado: (2022)

Azd-1222/bbv-152: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022)

Development of Nipah virus-specific IgM & IgG ELISA for screening human serum samples
por: Shete, Anita M., et al.
Publicado: (2022)

Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant
por: Shete, Anita M., et al.
Publicado: (2022)

Reduced severity of SARS-CoV-2 infection by Kappa variant of interest (B.1.617.1) in a healthcare worker post-vaccination from Gujarat, India
por: Sahay, Rima Rakeshkumar, et al.
Publicado: (2022)

Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees
por: Yadav, Pragya D., et al.
Publicado: (2022)

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
por: Ella, Raches, et al.
Publicado: (2021)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

AZD-1222/BBV-152: Central nervous system demyelination: 29 case reports
Publicado: (2022)

A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
por: Dotiwala, Farokh, et al.
Publicado: (2022)

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection
por: Yadav, Pragya D., et al.
Publicado: (2023)

Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
por: Vijayaraghavan, Radha, et al.
Publicado: (2023)

Inactivation of SARS-CoV-2 by gamma irradiation
por: Jain, Rajlaxmi, et al.
Publicado: (2021)

Genomic characterization, transcriptome analysis, and pathogenicity of the Nipah virus (Indian isolate)
por: Mohandas, Sreelekshmy, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021)

Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
por: Li, Jing-Xin, et al.
Publicado: (2021)

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
por: Sahay, Rima R., et al.
Publicado: (2022)

A case with SARS-CoV-2 reinfection from India
por: Munivenkatappa, Ashok, et al.
Publicado: (2022)

Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients
por: Deshpande, Gururaj Rao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6i6ptgopdn7fj2n54ujl7i1m54